Status:

COMPLETED

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Chronic Obstructive Pulmonary Disease (COPD)

Eligibility:

All Genders

40+ years

Phase:

PHASE3

Brief Summary

This study is designed to collect long term safety data of indacaterol (300 µg o.d.) in Japanese patients with moderate to severe COPD. Data from this study will be used for the registration of indaca...

Eligibility Criteria

Inclusion

  • 1\. Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines) and:
  • Smoking history of at least 20 pack-years
  • Post-bronchodilator FEV1 \<80% and ≥30% of the predicted normal value
  • Post-bronchodilator FEV1/FVC (forced vital capacity) \<70%

Exclusion

  • Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period
  • Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1
  • Patients with concomitant pulmonary disease
  • Patients with a history of asthma
  • Patients with diabetes Type I or uncontrolled diabetes Type II
  • Any patient with lung cancer or a history of lung cancer
  • Patients with a history of certain cardiovascular comorbid conditions
  • Patients who have been exposed to indacaterol previously. (Except for any patient who enrolled in Study CQAB149B1302)
  • Other protocol-defined inclusion/exclusion criteria may apply

Key Trial Info

Start Date :

March 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2010

Estimated Enrollment :

186 Patients enrolled

Trial Details

Trial ID

NCT00876694

Start Date

March 1 2009

End Date

October 1 2010

Last Update

November 8 2011

Active Locations (37)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (37 locations)

1

Novartis Investigator Site

Asahikawa, Japan

2

Novartis Investigator Site

Bunkyō City, Japan

3

Novartis Investigator Site

Gifu, Japan

4

Novartis Investigator Site

Hamamatsu, Japan